Erythema Nodosum During Adalimumab Therapy: An Idiopathic Transient Paradoxical Effect
American Journal of Internal Medicine
Volume 3, Issue 5, September 2015, Pages: 210-212
Received: Aug. 16, 2015; Accepted: Aug. 20, 2015; Published: Aug. 29, 2015
Views 4520      Downloads 73
Authors
Ilker Ilhanli, Department of Physical Medicine and Rehabilitation, School of Medicine, Giresun University, Giresun, Turkey
Yunus Durmaz, Department of Physical Medicine and Rehabilitation, Division of Rheumatology, School of Medicine, Cumhuriyet University, Sivas, Turkey
Necip Guder, Physical Medicine and Rehabilitation State Hospital, Giresun, Turkey
Kıvanc Cengiz, Department of Physical Medicine and Rehabilitation, Division of Rheumatology, School of Medicine, Cumhuriyet University, Sivas, Turkey
Article Tools
Follow on us
Abstract
Contrary to their undoubted efficacy on rheumatologic diseases, potential for developing skin lesions with Tumor necrosis alpha blockers (Anti-TNF alpha) is an important question in our minds. Although we know, most of the studies and case reports in the literature show that adalimumab is an effective treatment agent on erythema nodosum, we should keep in mind this lesion as a rare paradoxical side-effect. Here we present a case of idiopathic transient erythema nodosum during adalimumab therapy.
Keywords
Anti-TNF Alpha, Adalimumab, Rheumatoid Arthritis, Erythema Nodosum
To cite this article
Ilker Ilhanli, Yunus Durmaz, Necip Guder, Kıvanc Cengiz, Erythema Nodosum During Adalimumab Therapy: An Idiopathic Transient Paradoxical Effect, American Journal of Internal Medicine. Vol. 3, No. 5, 2015, pp. 210-212. doi: 10.11648/j.ajim.20150305.13
References
[1]
Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis.Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602.
[2]
Moreland LW,Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomised, controlled trial. Ann Intern Med 1999; 130: 478-486.
[3]
Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
[4]
Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003; 48: 218-226.
[5]
Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-1675.
[6]
Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193.
[7]
Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385-390.
[8]
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-1939.
[9]
Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomised, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-1411.
[10]
Bleumink GS, ter Borg EJ, Ramselaar CG, Stricker BHC. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40: 1317-1319.
[11]
Brion PH, Mittal HA, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis (letter). Ann Inter Med 1999; 131: 634.
[12]
Kent PD, Davis JM, Davis MDP, Matteson EL. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum 2002; 46: 2257-2258.
[13]
Misery L, Perrot JL, Gentil PA, Pallot PB, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol 2002; 146: 334-335.
[14]
Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP, Pascual JC. Cutaneous drug eruption to infliximab: Report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138: 1258-1259.
[15]
Wright RC. Atopic dermatitis-like eruption precipitated by infliximab. J Am Acad Dermatol 2003; 49: 160-161.
[16]
Flendrie M, Vissers W, Creemers M, Jong E, Kerkhof P, Riel P. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005; 7: 666-676.
[17]
Goodfield MJD, Jones SK, Veale DJ. The connective tissue diseases. Textbook of Dermatology, Vol. 2, 7th edn. Blackwell Science, Oxford, 2004; 56: 138-140.
[18]
Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005; 4: 637-641.
[19]
Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 2004; 15: 280-294.
[20]
Saripalli YV, Gaspari AA. Focus on biologics that affect therapeutic agents in dermatology: J Drugs Dermatol 2005; 4: 233-245.
[21]
Beuthien W, Mellinghoff H-U, von Kempis J. Skin reaction to Adalimumab. Arthritis Rheum 2004; 50: 1690-1692.
[22]
Delle Sedie A, Bazzichi L, Bpmbardieri S, Riente L. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab.Scand J Rheumatol 2007; 36(5): 403-404.
[23]
Rajakulendran S, Deighton C. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug. Curr Drug Saf 2006; 1(3): 259-264.
[24]
Zippi M, Pica R, De Nitto D, Paoluzi P. Biological therapy for dermatological manifestations of inflammatory bowel disease. World J Clin Cases 2013; 1(2): 74-78.
[25]
Dalmau-Carolà J. Erythema nodosum, a "red flag" during anti-TNF therapy. Int J Rheum Dis 2013; 16(4): 493-494.
[26]
Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease. Clin Gastroenterol Hepatol 2015; 13(5): 940-948.
[27]
Benítez-Gutiérrez L, Tutor-de Ureta P, Mellor-Pita S, Yebra-Bango M. Refractory chronic erythema nodosum treated with adalimumab. Rev Clin Esp (Barc) 2013; 213(9): 466-467. [Article in Spanish]
[28]
Ortego-Centeno N, Callejas-Rubio JL, Sanchez-Cano D, Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2007; 21(3): 408-410.
[29]
Quin A, Kane S, Ulitsky O. A case of fistulizing Crohn's disease and erythema nodosum managed with adalimumab.Nat Clin Pract Gastroenterol Hepatol 2008; 5(5): 278-281.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186